Related Experiment Video
Updated: Aug 26, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
Cardiac contractility and conduction: a comparison of antihypertensives
1Division of Cardiology, Oregon Health Sciences University, Portland 97201-3098.
Insights
This review examines first-line antihypertensive agents, focusing on their cardiac effects in patients with cardiovascular disease. Diuretics and ACE inhibitors have minimal cardiac impact, while beta-blockers and calcium channel blockers offer specific benefits and considerations.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The 1988 Joint National Committee report recommended four classes of first-line antihypertensive agents.
- Understanding the cardiac effects of these agents is crucial for patients with co-existing cardiovascular diseases.
Purpose of the Study:
- To review the cardiac effects of first-line antihypertensive agents.
- To assess the impact of these agents on heart rate, atrioventricular nodal conduction, and myocardial contractility.
Main Methods:
- Review of existing literature on antihypertensive agents.
- Analysis of effects on cardiac parameters in patients with cardiovascular conditions.
Main Results:
- Diuretics and angiotensin-converting enzyme inhibitors exhibit no significant direct cardiac effects.
- Beta-blockers can inhibit cardiac stimulation and benefit patients post-myocardial infarction.
- Calcium channel blockers, though heterogeneous, can be selected for potent peripheral vasodilation to minimize cardiac effects.
Conclusions:
- The choice of antihypertensive agent should consider its specific cardiac effects, especially in patients with cardiovascular disease.
- Newer agents like isradipine show promise for targeted arterial vasodilation and improved safety profiles.
Abstract:
The four classes of first-line antihypertensive agents recommended in the 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure are reviewed here. Particular consideration is given to the effects of these agents on heart rate, atrioventricular nodal conduction, and myocardial contractility in patients with other cardiovascular diseases. Diuretics and angiotensin-converting enzyme inhibitors have no significant direct effects on cardiac function. beta-Blockers inhibit catecholamine stimulation of the heart and may be particularly beneficial in treating patients with a history of myocardial infarction. Calcium channel blockers reduce blood pressure by dilating arterial resistance vessels. They are structurally heterogeneous and highly selective in their sites of action. As a consequence, cardiac effects can be minimized by selecting a calcium channel blocker with more potent peripheral vasodilatory effects. A new calcium channel blocker, isradipine, currently undergoing clinical trials, is highly selective for arterial smooth muscle and appears to be a safe and effective antihypertensive agent.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

